KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

Related Keywords

Matthewa Powell ,Bhavana Pothuri ,Ursulaa Matulonis ,Shannonn Westin , ,New England Journal ,Endometrial Cancer ,Keynote 775 ,Mismatch Repair ,Pembrolizumab ,Lenvatinib ,Chemotherapy ,Paclitaxel ,Doxorubicin ,Checkpoint Inhibition ,Nrg Gy025 ,Nrg Gy020 ,Ruby Trial ,Nrg Gy018 ,Gog 3053 ,